Latest Structure Therapeutics News & Updates
See the latest news and media coverage for Structure Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biopharmaceutical company developing oral small molecule therapeutics
structuretx.com- Headquarters
- South San Francisco, United States
- Founded year
- 2017
- Company type
- Public company
- Number of employees
- 50–225
Last updated
Latest news about Structure Therapeutics
In short: Structure Therapeutics reported positive Phase 2 weight loss data for aleniglipron and secured $1.5B in cash to fund operations through 2028.
Company announcements
-
Structure Therapeutics reports Q1 2026 financial results
Cash at $1.5B funds operations through 2028. Positive Phase 2 aleniglipron data with 16.3% weight loss. Phase 3 initiation on track for Q3 2026.
-
Structure Therapeutics appoints Matthew Lang as COO and General Counsel
Lang brings over 15 years of biopharma experience in legal, strategy, and operations. He previously served at Metsera, Lyell Immunopharma, and Myovant.
-
Structure Therapeutics announces positive Phase 2 trial data
The data from the ACCESS II trial for aleniglipron supports Phase 3 preparation and offers a convenient oral option for obesity treatment.
-
Structure Therapeutics reports positive Phase 2 topline data
Aleniglipron achieves 16.3% placebo-adjusted weight loss at 44 weeks. Phase 3 initiation is on track for 2H 2026.
Media coverage
-
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the...
-
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today...
-
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.
-
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.
Track Structure Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Structure Therapeutics competitors & trending companies
Browse news for competitors to Structure Therapeutics and other trending companies.
Pila Pharma
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove